Omnicell (NASDAQ:OMCL) Shares Gap Up – Here’s What Happened

Omnicell, Inc. (NASDAQ:OMCL) gapped up prior to trading on Thursday . The stock had previously closed at $47.45, but opened at $49.90. Omnicell shares last traded at $50.65, with a volume of 107,030 shares.

Omnicell News Roundup

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: KeyBanc upgraded Omnicell on signs of traction for the Titan XT platform and competitive conversions, highlighting potential revenue and margin upside from product adoption. KeyBanc upgrades Omnicell
• Neutral Sentiment: Consensus estimates cited in the reports still center near $1.09 FY earnings, so Zacks’ cuts reflect one firm’s downward revisions rather than a broad analyst pullback. MarketBeat OMCL summary
• Negative Sentiment: Zacks Research lowered a string of quarterly and full‑year EPS forecasts across FY2025–FY2027 (examples: FY2025 from $1.01→$0.92, FY2026 from $1.03→$0.93, FY2027 from $1.10→$1.00) and cut multiple quarter estimates — maintaining a “Hold” rating. Those cuts reduce near‑term earnings expectations and create downside risk for a stock trading at a high P/E, which tends to be sensitive to EPS revisions. Zacks Research estimate cuts

Analyst Ratings Changes

OMCL has been the topic of several research analyst reports. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a research report on Wednesday. Wells Fargo & Company lifted their price objective on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Benchmark boosted their price objective on Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Omnicell has an average rating of “Hold” and an average price target of $47.83.

Omnicell Trading Up 0.3%

The stock has a market cap of $2.28 billion, a PE ratio of 118.00, a price-to-earnings-growth ratio of 5.21 and a beta of 0.77. The company’s 50-day moving average price is $41.06 and its 200 day moving average price is $34.25. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently modified their holdings of OMCL. SG Americas Securities LLC increased its position in shares of Omnicell by 219.4% during the 4th quarter. SG Americas Securities LLC now owns 20,547 shares of the company’s stock worth $931,000 after purchasing an additional 14,114 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock worth $11,698,000 after purchasing an additional 117,556 shares during the period. Diversified Trust Co. lifted its position in shares of Omnicell by 7.5% during the fourth quarter. Diversified Trust Co. now owns 7,965 shares of the company’s stock worth $361,000 after purchasing an additional 555 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Omnicell during the 3rd quarter worth approximately $224,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Omnicell during the 3rd quarter worth approximately $1,924,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.